Genkyotex Plans 'Solo' Pivotal Trials After Lead Product Hits Phase II PBC Targets
Executive Summary
The CEO Genkyotex says its lead molecule therapy's mechanism of action has been validated by good short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial.